AstraZeneca will invest $17.7 million in a five-year partnership with the University of Manchester to focus on using bioinformatics tools in clinical trials to make more personalized treatment decisions for oncology patients.
As part of the collaboration, AstraZeneca will provide $17.7 million to support clinical bioinformatics research led by a dedicated team of investigators within the recently established Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre.
According to AstraZeneca, projects will include the development of a new bioinformatics system to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time, presenting the information in the form of graphs that can be easily interpreted by clinicians to help tailor the treatment for patients.
Read the AstraZeneca press release
